Alignment Healthcare Inc research snapshot
ALHC AI stock analysis reads Alignment Healthcare Inc as a Medicare Advantage insurer that is scaling revenue toward $5.2 billion in 2026 while moving into profitability. At the August 4, 2026 data cutoff, ALHC traded near $14.66 with a verified market capitalization near $3.04 billion, down roughly 38% in a month after a whistleblower lawsuit and downgrade pressure. The company beat Q2 2026 estimates with revenue of $1.34 billion versus $1.31 billion consensus, net income of $36.6 million, and EPS of $0.25 versus $0.20 consensus, then raised full-year guidance to revenue of $5.20 to $5.23 billion and adjusted EBITDA of $145 to $163 million. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$14.66
Market cap
$3.04 billion
AI score
52 / 100
Rating
Fast-growing Medicare Advantage provider that beat Q2 2026 estimates and raised full-year guidance, now turning profitable, but a whistleblower lawsuit, ongoing securities fraud investigations, and a roughly 38% one-month stock decline create high uncertainty
Trend status
ALHC fell about 37.6% in the four weeks to the August 3, 2026 snapshot, breaking below the $17-$18 zone that had held through late July and trading near its $12.97 52-week low. The stock remains well below the $25.12 52-week high and the $28.59 all-time high from May 2021.
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Alignment Healthcare is a tech-enabled Medicare Advantage insurer serving seniors through its Alignment Health Plan brand. Q2 2026 showed membership of 294,100, up 31% year over year, revenue of $1.34 billion, and net income of $36.6 million, the strongest profit quarter in company history. | Medium |
| Moat | Moat comes from state Medicare Advantage licenses, provider network relationships, the AVA AI care stratification platform, and member retention. Large competitors such as UnitedHealth, Humana, and Centene have deeper resources, and MA plan differentiation is hard to sustain long term. | Low-medium |
| Management | Founder and CEO John Kao has led the company since 2013, taking it public in 2021. Q2 2026 execution was strong and management raised all full-year guidance metrics. However, the July 8, 2026 whistleblower lawsuit filed by a former executive, along with securities fraud investigations, raises governance questions that warrant monitoring. | Medium |
| Financial trend | Revenue grew from roughly $1.5 billion in 2021 to $3.95 billion in FY2025 and is guided to about $5.2 billion for 2026. Q2 2026 delivered net income of $36.6 million and adjusted EBITDA of $68 million at a 5.1% margin, with first-half adjusted EBITDA up 60% year over year. | Medium-high |
| Valuation | At $14.66 with a P/E near 77x on TTM EPS of $0.19, the stock still prices in meaningful profit growth, though that is far below the roughly 220x level seen in July. Forward P/S is about 0.58x against the $5.20 billion 2026 revenue guide, which is more reasonable for a managed care company. | Medium |
| Technical trend | The stock is in a strong downtrend, down roughly 38% in a month and trading near its $12.97 52-week low after breaking below prior support near $17-$18. TradingView technicals read as strong sell, with RSI in oversold territory after the sharp decline. | Medium |
| Risk level | High risk. Key risks include the whistleblower lawsuit and securities fraud investigations, thin profit margins, regulatory changes to Medicare Advantage including Star ratings and the V28 risk model, medical cost ratio pressure from a higher-acuity new member mix, and small-cap stock volatility. | Medium-high |
| AI confidence | High for verified financial data and analyst consensus, low-medium for outcome scenarios given the lawsuit uncertainty and the early profitability transition. | Medium data confidence |
| Investment certainty | Low-medium certainty. The page frames scenarios and monitoring rules, not a buy or sell instruction. | Low-medium |
ALHC AI stock forecast
The ALHC AI stock forecast uses scenario ranges around the $14.66 quote and the $5.20 billion 2026 revenue guide. The framework produced a bearish area near $9 to $14, a base area near $18 to $23, and a bullish area near $26 to $32, reflecting legal risk in the conservative case and sustained Medicare Advantage growth plus margin expansion in the optimistic case.
$26 to $32
More likely if Alignment Healthcare resolves the whistleblower lawsuit favorably, sustains roughly 30% membership and revenue growth, delivers the raised 2026 guidance, and the market re-rates the stock toward 1.0 to 1.2x forward revenue, consistent with the highest analyst targets near $28 to $30.
$18 to $23
More likely if ALHC grows revenue about 20% in 2027, gradually improves medical cost ratio as membership cohorts mature, the lawsuit does not escalate into a restatement, and the stock trades near the analyst average target of $21.83 at roughly 0.75 to 0.9x forward revenue.
$9 to $14
More likely if the whistleblower lawsuit leads to material financial restatements or regulatory action, medical cost ratio deteriorates from the higher-acuity member mix, Star ratings or the V28 risk model cut reimbursement, or competition from larger insurers intensifies.
ALHC AI technical analysis
ALHC AI technical analysis shows a stock in a sharp downtrend, down roughly 38% in a month and trading near its 52-week low after breaking below prior support near $17-$18. The stock traded between $12.97 and $25.12 over the past 52 weeks as of the August 4, 2026 data cutoff, with TradingView technicals reading strong sell.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $14.66 | Google Finance quote snapshot around the August 3, 2026 cutoff placed ALHC near $14.66, with TradingView showing $14.16 on the same session. |
| Near support | $13.00 to $13.70 | The August 3 session low reached $13.70, so the $13.00 to $13.70 zone is the near-term floor ahead of the 52-week low. |
| Key support | $12.97 (52-week low) | The 52-week low near $12.97 is the major support level set during the current sell-off. A decisive close below it would signal that selling is not exhausted. |
| Below key support | $11.00 to $12.00 | If $12.97 breaks, the next reference zone is $11 to $12 before the post-2024 recovery area becomes relevant. |
| Near resistance | $16.00 to $17.50 | The zone between $16 and $17.50 was the early breakdown area in the sell-off and now acts as initial resistance, with the low end near the Barclays price target of $16. |
| Major resistance | $20.00 to $21.00 | The area near $20 to $21 was where ALHC traded before the July 8 lawsuit news and aligns with the TD Cowen target of $21. It is a key level for any stabilization attempt. |
| 52-week high | $25.12 | The 52-week high of $25.12 is the primary resistance level. A return to it would require the legal overhang to clear and margin trends to improve. |
| All-time high | $28.59 | The all-time high from May 5, 2021 represents the ultimate resistance and would require sustained profitability and investor confidence. |
| Momentum | RSI oversold; TradingView strong sell | RSI sits in oversold territory after the roughly 38% one-month decline. TradingView technicals currently read strong sell on the daily timeframe. |
| Volume | Average volume near 5.10 million shares | Volume was elevated during the sell-off and around the earnings and downgrade news, confirming active distribution. Above-average volume on recovery days would signal buying conviction. |
| Volatility | Beta of 0.62 (1Y) to 1.05; volatility near 8.8% | TradingView reports 8.76% daily volatility with a 1-year beta of 0.62, while Google Finance shows a beta near 1.05. Elevated single-stock volatility is typical for a small-cap managed care name. |
| Invalidation | Close below $12.97 | A decisive close below the $12.97 52-week low would suggest the selling pressure is not exhausted and opens a move toward the $11 to $12 zone. |
ALHC AI trading strategy
The ALHC AI trading strategy is a rules-based research framework for monitoring a fast-growing, now-profitable Medicare Advantage company with active litigation risk. It is not personal advice and should be paired with fresh chart data, lawsuit developments, upcoming earnings, position sizing, and a defined invalidation level.
Given the strong downtrend, a trend-following approach would wait for ALHC to stabilize above $16 on above-average volume, form a higher low above $14, and reclaim the 20-day moving average before considering a long position. Entering before that structure appears is fighting the trend.
A failure to hold $12.97 or continued volume-led selling would suggest the downtrend is intact. Small-cap healthcare stocks can gap on news, so position sizing should be conservative.
ALHC is deeply oversold after a roughly 38% one-month decline while Q2 fundamentals and guidance are strong. A mean-reversion trader could watch the $13 to $14 zone for a bullish reversal candle or an RSI oversold signal, targeting a bounce back toward $16 to $18.
The whistleblower lawsuit creates binary risk. A material adverse ruling or financial restatement could drive the stock below support regardless of the technical setup. A maximum loss rule of 7-10% is prudent.
Track the whistleblower lawsuit and securities fraud investigation developments, quarterly membership growth, medical cost ratio trends, Star ratings, the V28 risk model, 2027 bid season and enrollment growth, insider trading patterns, and analyst rating changes.
Reduce confidence if the lawsuit expands, medical cost ratio deteriorates, revenue growth slows below 15%, Star ratings slip, or the company needs to raise capital. The thin profit margin provides little earnings cushion for adverse events.
Investment research summary
Alignment Healthcare offers Medicare Advantage insurance plans to seniors, using the AVA AI care stratification platform and Care Anywhere clinical teams to manage member health and control costs. Customers choose Alignment for personalized service and benefits, while the company earns premium revenue from Medicare contracts and manages its medical cost ratio to generate profit.
The moat includes state-level Medicare Advantage licenses, provider network relationships built since 2013, and proprietary AI-driven care coordination. The AVA model helps target the roughly 10% of members that drive a large share of hospital admissions. However, UnitedHealth, Humana, and Centene can outspend Alignment on technology, benefits, and market presence, keeping the moat narrow.
The thesis fails if the whistleblower lawsuit filed on July 8, 2026 by a former executive escalates into material restatements or regulatory sanctions, or if the securities fraud investigations broaden. It also fails if medical cost ratio deteriorates under the higher-acuity new member mix, if Star ratings or the V28 risk model cut reimbursement, or if larger competitors use scale to underprice Alignment in its core markets.
Founder and CEO John Kao has grown the company from startup to about $5.2 billion in 2026 guided revenue since 2013. Q2 2026 showed strong execution with a beat and raised guidance. The whistleblower lawsuit alleging financial manipulation, the related securities investigations, and incentives tied to a $55 share price are governance concerns that require monitoring.
Alignment Healthcare operates in a growing Medicare Advantage market as more seniors choose MA plans over traditional Medicare, with the aging U.S. population providing a structural tailwind. Management targets about 20% enrollment growth for 2027. Regulatory scrutiny of MA marketing, Star ratings, and the V28 risk model could create headwinds, and some competitors are expected to be more aggressive in 2027.
At roughly $14.66 and about 77x trailing earnings, traditional value metrics still offer little margin of safety, though the P/E has compressed from roughly 220x in July. Forward P/S of about 0.58x against the $5.20 billion 2026 revenue guide is more reasonable. The scenario framework estimates a base case near $20, suggesting the current price partially discounts the legal risk but does not offer a wide safety margin.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ALHC price | $14.66 (TradingView snapshot $14.16) | Google Finance + TradingView cross-verified | August 3, 2026 |
| Market capitalization | $3.04 billion, verified as $14.66 x 207.44M shares | financial_rigor.py market cap verification (0.04% vs Google, 1.3% vs TradingView) | August 3, 2026 |
| Shares outstanding | 207.44 million (float 196.45 million) | Google Finance / TradingView | August 3, 2026 |
| 52-week high | $25.12 | Google Finance | August 3, 2026 |
| 52-week low | $12.97 | Google Finance | August 3, 2026 |
| All-time high / low | $28.59 (May 5, 2021) / $4.46 (Apr 3, 2024) | TradingView | August 3, 2026 |
| TTM GAAP EPS | $0.19 (Google Finance) to $0.20 (TradingView) | Google Finance + TradingView cross-verified | August 3, 2026 |
| P/E ratio (TTM) | About 77x, verified as $14.66 / $0.19 (TradingView ~100x) | financial_rigor.py valuation verification | August 3, 2026 |
| Q2 2026 revenue | $1.34 billion, up 32% YoY (beat $1.31B estimate) | Google Finance earnings + Q2 2026 earnings call | July 30, 2026 |
| Q2 2026 EPS | $0.25 (beat $0.20 estimate); TradingView reported $0.17 vs $0.13 | Google Finance earnings / TradingView (sources differ) | July 30, 2026 |
| Q2 2026 net income | $36.6 million (vs $15.7 million a year ago) | Google Finance / AP earnings snapshot | July 30, 2026 |
| Q2 2026 adjusted EBITDA | $68 million, 5.1% margin, up 48% YoY | Q2 2026 earnings call | July 30, 2026 |
| Q2 2026 membership | 294,100, up 31% YoY | Q2 2026 earnings call | July 30, 2026 |
| FY2026 raised guidance | Revenue $5.20 to $5.23 billion; adjusted EBITDA $145 to $163 million | Q2 2026 earnings call | July 30, 2026 |
| Fiscal year 2025 revenue | $3.95 billion | TradingView financials | August 3, 2026 |
| Analyst consensus | 6 Buy, 2 Hold, 0 Sell; average target $21.83 | Google Finance analyst ratings | August 3, 2026 |
| Analyst price target range | $16.00 to $30.00 | Google Finance + TradingView analyst targets | August 3, 2026 |
| Raymond James rating change | Downgraded Strong Buy to Outperform, target $19 from $22 (Aug 3, 2026) | StreetInsider analyst note | August 3, 2026 |
| Average volume | 5.10 million shares (elevated during sell-off) | Google Finance | August 3, 2026 |
| Whistleblower lawsuit | Filed July 8, 2026 by former executive Hakan Kardes alleging accounting irregularities and inflated Adjusted EBITDA; stock fell 16% that day | Business Wire / press reports | July 28, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell ALHC stock. Forecast scenarios are based on available public data, technical snapshots, and stated assumptions as of the data cutoff date and may be wrong. Always verify current filings, prices, risks, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
